Monoclonal antibody-based targeted therapy in breast cancer.

Kadri Altundag, Francisco J Esteva, Banu Arun
{"title":"Monoclonal antibody-based targeted therapy in breast cancer.","authors":"Kadri Altundag,&nbsp;Francisco J Esteva,&nbsp;Banu Arun","doi":"10.2174/1568011053174846","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in molecular biology have identified tumor markers that not only predict prognosis and therapeutic response but may also function as potential therapeutic targets. Activated growth factor receptors induce breast cancer cells to proliferate, invade, and metastasize in experimental models. Overexpression of growth factor receptors has been associated with a poor clinical outcome in breast cancer patients. Biological therapy with monoclonal antibody directed against growth factor receptor pathways became important targeted therapy in breast cancer and is being pursued on various fronts. The anti-HER2 antibody trastuzumab is approved in the metastatic setting and is now trying to find the place in the adjuvant setting. Phase II and III studies with antibodies directed against VEGF and EGFR are also ongoing.</p>","PeriodicalId":10914,"journal":{"name":"Current medicinal chemistry. Anti-cancer agents","volume":"5 2","pages":"99-106"},"PeriodicalIF":0.0000,"publicationDate":"2005-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568011053174846","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry. Anti-cancer agents","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1568011053174846","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 21

Abstract

Advances in molecular biology have identified tumor markers that not only predict prognosis and therapeutic response but may also function as potential therapeutic targets. Activated growth factor receptors induce breast cancer cells to proliferate, invade, and metastasize in experimental models. Overexpression of growth factor receptors has been associated with a poor clinical outcome in breast cancer patients. Biological therapy with monoclonal antibody directed against growth factor receptor pathways became important targeted therapy in breast cancer and is being pursued on various fronts. The anti-HER2 antibody trastuzumab is approved in the metastatic setting and is now trying to find the place in the adjuvant setting. Phase II and III studies with antibodies directed against VEGF and EGFR are also ongoing.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于单克隆抗体的乳腺癌靶向治疗。
分子生物学的进步已经确定了肿瘤标志物,这些标志物不仅可以预测预后和治疗反应,还可以作为潜在的治疗靶点。在实验模型中,激活的生长因子受体诱导乳腺癌细胞增殖、侵袭和转移。生长因子受体的过度表达与乳腺癌患者的不良临床结果有关。针对生长因子受体途径的单克隆抗体生物治疗成为乳腺癌重要的靶向治疗,并在各个方面得到了发展。抗her2抗体曲妥珠单抗已被批准用于转移性治疗,目前正试图在辅助治疗中找到一席之地。针对VEGF和EGFR抗体的II期和III期研究也在进行中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Lanthanides as anticancer agents. Current drug therapy for prostate cancer: an overview. Sulfo-quinovosyl-acyl-glycerol (SQAG), a eukaryotic DNA polymerase inhibitor and anti-cancer agent. Lycopene: a review of its potential as an anticancer agent.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1